Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241.
This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website (www.transgene.com).
It includes the following documents:
the Annual Financial Report;
the Board of Directors’ Corporate Governance Report;
the Statutory Auditors’ Reports;
information on the Company’s share capital, including the share buyback program;
information on the Statutory Auditors’ fees.
The Universal Registration Document also includes information on the Company’s Environmental, Social and Governance (ESG) factors.
Attachment